CEACAM5 and neoplasm: Wu et al. developed a VHH-based drug conjugate based on a VHH targeting the carcinoembryonic antigen conjugated with a topoisomerase 1 inhibitor, which accumulated more effectively in tumors and inhibited tumor progression more efficiently compared with its conventional ADC [16].